Literature DB >> 23069892

Effects of endothelial nitric oxide synthase tagSNPs haplotypes on nitrite levels in black subjects.

Ingrid F Metzger1, Marcelo R Luizon, Riccardo Lacchini, Marilia H Ishizawa, Jose E Tanus-Santos.   

Abstract

Haplotypes formed by clinically relevant polymorphisms in the endothelial nitric oxide synthase (eNOS) gene have been associated with variations in endogenous nitric oxide (NO) formation in white and black subjects. We examined whether further genetic variation and haplotypes of the eNOS gene, represented by the rs3918188, rs743506 and rs7830 tagSNPs (polymorphisms that represent the information of neighboring SNPs in linkage disequilibrium) affect endogenous NO formation in 181 healthy black subjects. We measured whole blood nitrite concentration as a marker of endogenous NO formation for each subject. We found that the heterozygotes CA for the tagSNP rs7830 (P=0.0278, OR=0.4839, CI 95% 0.2567-0.9121), as well as the haplotype "C-G-A" (P=0.0068), were more common in subjects with low circulating whole blood nitrite concentrations compared with subjects with high circulating whole blood nitrite concentrations, although the genotype finding is not significant after correction for multiple comparisons. These findings suggest that these tagSNPs of the eNOS gene and haplotypes are associated with low levels of nitric oxide production in blacks, and could be used as a marker of cardiovascular risk.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23069892     DOI: 10.1016/j.niox.2012.10.002

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  7 in total

1.  Endothelial nitric oxide synthase polymorphisms and haplotypes in genetic epidemiology and pharmacogenetics: remarks regarding a lack of association on the risk of myocardial infarction.

Authors:  Marcelo Rizzatti Luizon
Journal:  Mol Biol Rep       Date:  2014-01-07       Impact factor: 2.316

2.  Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability.

Authors:  Gustavo H Oliveira-Paula; Fernanda Borchers Coeli-Lacchini; Letícia Perticarrara Ferezin; Graziele C Ferreira; Lucas C Pinheiro; Waynice N Paula-Garcia; Luis V Garcia; Jose E Tanus-Santos; Riccardo Lacchini
Journal:  Eur J Clin Pharmacol       Date:  2021-01-07       Impact factor: 2.953

3.  Fetal hemoglobin-boosting haplotypes of BCL11A gene and HBS1L-MYB intergenic region in the prediction of clinical and hematological outcomes in a cohort of children with sickle cell anemia.

Authors:  Rahyssa Rodrigues Sales; Bárbara Lisboa Nogueira; André Rolim Belisário; Gabriela Faria; Fabiola Mendes; Marcos Borato Viana; Marcelo Rizzatti Luizon
Journal:  J Hum Genet       Date:  2022-09-27       Impact factor: 3.755

4.  The effects of endothelial nitric oxide synthase tagSNPs on nitrite levels and risk of hypertension and obesity in children and adolescents.

Authors:  J A de Miranda; R Lacchini; V A Belo; C M M Lanna; J T Sertorio; M R Luizon; J E Tanus-Santos
Journal:  J Hum Hypertens       Date:  2014-06-19       Impact factor: 3.012

5.  NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia.

Authors:  Daniela A Pereira; Valeria C Sandrim; Ana C Palei; Lorena M Amaral; Vanessa A Belo; Riccardo Lacchini; Ricardo C Cavalli; Jose E Tanus-Santos; Marcelo R Luizon
Journal:  Pharmacogenomics       Date:  2021-05-04       Impact factor: 2.638

6.  An Investigation of the Relationship between the eNOS Gene Polymorphism and Diagnosed Migraine.

Authors:  S Güler; H Gürkan; H Tozkir; N Turan; Y Çelik
Journal:  Balkan J Med Genet       Date:  2015-04-10       Impact factor: 0.519

7.  Pharmacogenomics of Hypertension and Preeclampsia: Focus on Gene-Gene Interactions.

Authors:  Marcelo R Luizon; Daniela A Pereira; Valeria C Sandrim
Journal:  Front Pharmacol       Date:  2018-02-28       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.